Regorafenib and Cetuximab in Patients With Advanced Malignancy
Status:
Completed
Trial end date:
2020-03-27
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of the
combination of regorafenib and cetuximab that can be given to patients with advanced solid
tumors. The safety and effectiveness of this drug combination will also be studied.